Efficacy analysis of drug-eluting beads chemoembolization in the treatment of liver cancer patients who are waiting for fiver transplantation
10.3760/cma.j.issn.1007-8118.2019.04.002
- VernacularTitle:载药微球化疗栓塞在肝癌患者肝移植等待期间应用的疗效分析
- Author:
Hao WANG
1
;
Guang CHEN
;
Haijun GAO
;
Lianfang WEN
;
Penghui WANG
;
Yixin YANG
;
Li ZHANG
;
Qingchan DING
Author Information
1. 天津市第一中心医院放射科 300192
- Keywords:
Liver neoplasms;
Liver transplantation;
Drug-eluting beads;
Embolization,therapeutic
- From:
Chinese Journal of Hepatobiliary Surgery
2019;25(4):246-248
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the value of DEB-TACE before liver transplantation for hepatocellular carcinoma patients.Methods From Jan.2016 to Jan.2018,23 patients received DEB-TACE before liver transplantation for hepatocellular carcinoma were induced.Complications evaluation was followed up after interventional therapy.4 weeks after the intervention,the imaging examination was performed to examine the tumor response rate depond on mRECIST,the pathological conditions and tumor free survival were studied in the patients who received liver transplantation.Results The achievement ration of operation was 100％ in 23 patients.23 patients received 24 times successfully,1 patient received DEB-TACE twice,and the remaining 22 patients received DEB-TACE once.No serious complications occurred.Eighteen patients (78.3％,18/23) had postembolic syndrome after interventional therapy,mainly fever and pain.Four weeks after DEB-TACE,the complete response rate was 47.8％ (11/23),partial response rate was 30.4％ (7/23),disease stability rate was 21.7％ (5/23).All the 23 patients were included in the waiting list for transplantation.Among them,15 cases received liver transplantation.Pathological results showed that the total necrosis rate was 53.3％ (8/15),and the tumour necrosis rate in 4 of them was less than 50％.The average tumour necrosis rate of the neoplasm was 75.0％.The 15 patients who received liver transplantation were alive with no tumor recurrence.Conclusion DEB-TACE is a safe and effective treatment for patients suffered from hepatocellular carcinoma in waiting for liver transplantation.However,due to the short time of DEBs in China,further research is needed.
